FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry. Described is acylated, stabilised with respect to proteases insulin. Application of the described insulin for the production of a pharmaceutical composition for the treatment or prevention of hyperglycaemia, type 2 diabetes mellitus, impaired tolerance to glucose and type 1 diabetes mellitus is presented.
EFFECT: invention makes it possible to obtain the insulin analogues, stable to proteases.
24 cl, 11 dwg, 1 tbl, 184 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEASE-RESISTANT INSULIN ANALOGUES | 2007 |
|
RU2524150C2 |
| INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS | 2011 |
|
RU2598273C2 |
| INSULIN ANALOGUES WITH ACYL AND ALKYLENE GLYCOL GROUP | 2008 |
|
RU2514430C2 |
| NOVEL INSULIN DERIVATIVES AND USE THEREOF | 2015 |
|
RU2684456C2 |
| NOVEL DERIVATIVE OF INSULIN ANALOGUE | 2014 |
|
RU2673185C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN | 2017 |
|
RU2758367C2 |
| POLYPEPTIDES | 2012 |
|
RU2669999C2 |
| HYBRID PROTEIN CONTAINING FRAGMENTS OF FLUORESCENT PROTEINS AND ITS APPLICATION | 2020 |
|
RU2801248C2 |
| INSULIN ANALOGUES CHARACTERIZED BY REDUCED AFFINITY OF BINDING TO INSULIN RECEPTORS | 2019 |
|
RU2816595C2 |
| INSULIN CONJUGATES | 2019 |
|
RU2809189C2 |
